Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease

por Rutgeerts, Paul, Schreiber, Stefan, Feagan, Brian, Keininger, Dorothy L., O’Neil, Liz, Fedorak, Richard N.
Publicado 2007